Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 929 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Orthomyxoviridae Infection Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT07149428
View directory record Official record
Conditions
Respiratory Tract Infection, Smell Disorder, Influenza, Rhinosinusitis, COVID-19, Depression, Parosmia, Hyposomia, Normosomia, Anosmia
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

NCT00377611
View directory record Official record
Conditions
Influenza
Interventions
Fluarix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
3,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
9
States / cities
Mobile, Alabama • Delray Beach, Florida • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 1 Interventional

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

NCT01086657
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 13, 2026, 8:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cigarette Smoke and Susceptibility to Influenza Infection

NCT00448617
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 13, 2026, 8:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vaccine Efficacy in Diabetic and Elderly Patients

NCT02675608
View directory record Official record
Conditions
Inflammation
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4

NCT00538512
View directory record Official record
Conditions
Influenza
Interventions
Fluzone, Flumist, Physiologic saline
Biological · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 49 Years
Enrollment
1,952 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • Mount Pleasant, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 13, 2026, 8:07 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07703514
View directory record Official record
Conditions
Influenza
Interventions
cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

NCT01147068
View directory record Official record
Conditions
Influenza
Interventions
0.5mL Intramuscular Injection
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Overland Park, Kansas • Omaha, Nebraska • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Not applicable Interventional

Influenza Diagnosis, Treatment and Surveillance With Xpert Flu

NCT01947049
View directory record Official record
Conditions
Influenza
Interventions
Rapid Influenza Testing with Xpert Flu
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Phoenix, Arizona • Sylmar, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

NCT01712984
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
38
States / cities
Hoover, Alabama • Huntsville, Alabama • Chandler, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 13, 2026, 8:07 AM EDT
Terminated No phase listed Observational Results available

Evaluation of a Screen and Treat Protocol for Influenza

NCT06207058
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Tricore, Inc
Other
Eligibility
5 Years and older
Enrollment
25 participants
Timeline
2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

NCT03293498
View directory record Official record
Conditions
Influenza
Interventions
NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

NCT04576702
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aIIV4c, IIV4c, aIIV4, RIV4
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Pregnant Women From Infectious Diseases

NCT01761799
View directory record Official record
Conditions
Influenza, Pertussis
Interventions
P3 Vaccine Promotion Package.
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
11
States / cities
Athens, Georgia • Atlanta, Georgia • Bogart, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

NCT00133471
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H9N2 vaccine, MF59 adjuvant
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 34 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 13, 2026, 8:07 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

NCT05170009
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil, Placebo, Oseltamivir
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 13, 2026, 8:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

NCT06160128
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, RSV, Influenza
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
400,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 8:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adjuvanted Influenza Vaccination Year 2 Follow-On Survey

NCT03599739
View directory record Official record
Conditions
Influenza, Influenza-like Illness, Influenza, Human
Interventions
Influenza
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

NCT04164212
View directory record Official record
Conditions
Influenza
Interventions
Flumist Quadrivalent Nasal Product
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 49 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

NCT01205581
View directory record Official record
Conditions
HIV, Cancer
Interventions
Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunologic Response to Influenza Vaccination in Children and Adolescents

NCT03614975
View directory record Official record
Conditions
Influenza, Human, Immune Response
Interventions
Flucelvax inactivated influenza vaccine, Fluzone inactivated influenza vaccine
Biological
Lead sponsor
Richard Zimmerman MD
Other
Eligibility
4 Years to 20 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

NCT01236040
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 13, 2026, 8:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza

NCT01390025
View directory record Official record
Conditions
Influenza, Human
Interventions
TCN-032, Placebo
Biological
Lead sponsor
Theraclone Sciences, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 13, 2026, 8:07 AM EDT